We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients.
- Authors
Bonomi, Philip; Fidler, Mary Jo; Shah, Palmi; Borgia, Jeffrey
- Abstract
Lung cancer continues to be a major worldwide health issue, with more than 50% of patients having incurable metastatic disease at diagnosis. Fortunately, the advanced lung cancer treatment landscape is changing rapidly as a result of the positive impact of effective inhibitors of tumor driver mutations, and the more recent discovery that immune modulation with anti-PD-1/PD-L1 monoclonal antibodies results in tumor regression and prolonged survival. While a relatively small subset of lung cancer patients are candidates for inhibitors of driver mutations, the majority of advanced lung cancer patients are candidates for an immunotherapy regimen. Many of these patients have cachexia, which is associated with increased cancer therapy toxicity and possibly reduced responsiveness to immunotherapy. Two ongoing cachexia trials, one testing a ghrelin analogue and the other testing a multimodal strategy, have endpoints which assess clinical benefit—weight gain and relief of anorexia/cachexia symptoms. Provided that the trial objectives are achieved, these treatment strategies will provide a way to relieve suffering and distress for cachectic cancer patients. While awaiting the results of these trials, it would be reasonable to consider designing studies testing cachexia treatments combined with first-line immunotherapy and chemotherapy–immunotherapy in stage IV lung cancer patients, with enhanced overall survival being one of the endpoints.
- Subjects
ANTINEOPLASTIC agents; CACHEXIA treatment; THERAPEUTIC use of monoclonal antibodies; CANCER chemotherapy; CANCER patients; IMMUNOTHERAPY; LUNG tumors; SURVIVAL; GHRELIN
- Publication
Cancers, 2019, Vol 11, Issue 11, p1619
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers11111619